Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HitGen Partners with Dorian to Discover Drugs for Age-Related Diseases

publication date: May 24, 2021

HitGen of Chengdu will collaborate with Dorian Therapeutics, a Bay Area biotech, to develop senoblockers, a new drug class designed fight aging by rejuvenating cells and tissues. Dorian's senoblockers act on epigenetic regulators to reverse the decrease in stem cell activity that slows cell regeneration in older people. This causes senescent cells to accumulate in the body and poison tissues. HitGen will use its DNA-encoded library platform to discover compounds that bind targets chosen by Dorian. HitGen will receive an upfront payment plus milestone payments from Dorian. More details....

Stock Symbol: (SHA: 688222)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.